echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Cinda Bio/Reindeer Medical's BCMA CAR-T cell therapy was recognized as a breakthrough therapeutic drug

    Cinda Bio/Reindeer Medical's BCMA CAR-T cell therapy was recognized as a breakthrough therapeutic drug

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 23, Cinda Biotech and Reindeer Medical jointly announced that the fully human BCMA chimeric antigen receptor autologous T cell injection developed by both parties (Cinda Biologics R&D code: IBI326; Reindeer Medical R&D code: CT103A) passed During the publicity period of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), the "breakthrough treatment drug variety" was included, and the proposed indication is relapsed/refractory multiple myeloma (R/R MM).


    Multiple myeloma is one of the most common blood cancers and a malignant disease in which clonal plasma cells proliferate abnormally.


    At the 61st American Annual Meeting of Hematology (ASH) held in 2019, Caribou Medical and Innovent Biosciences together orally reported the data of a clinical study of IBI326 in the treatment of relapsed/refractory multiple myeloma.


    In January 2021, the latest clinical research results of this innovative drug have been recognized by international authorities again-a team of Reindeer Medical and Professor Zhou Jianfeng from the Department of Hematology, Tongji Hospital of Huazhong University of Science and Technology The latest research results on the efficacy and safety of multiple myeloma were published in Blood, a well-known academic journal of hematology.


    Dr.


    Ms.


    IBI326 is a CAR-T cell therapy for B cell maturation antigen (BCMA) jointly developed by Innovent and Reindeer Medical Pharmaceuticals.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    Reference materials:

    [1] The BCMA CAR-T jointly developed by Cinda Biotech and Reindeer Medical has been recognized as a breakthrough therapeutic drug by the National Food and Drug Administration for the treatment of relapsed and refractory multiple myeloma.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.